Novartis (NVS) CEO Warns of Drug Pricing Policy Impact in 18 Months

AI Summary

Novartis (NVS) CEO Vas Narasimhan indicated that the U.S. drug pricing policy under President Trump, particularly the most favored nation (MFN) policy, could create significant challenges for drugmakers and patients in the next 18 months. This policy currently impacts around 5-10% of Medicaid sales for Novartis. The CEO emphasized the need for European and Japanese governments to modify their reward systems for drug innovation to avoid delayed access to new medicines. Furthermore, Germany's recent cost-cutting proposals could exacerbate the issue, raising concerns about the future of drug availability in these markets.